欢迎访问《中国临床药理学与治疗学》杂志官方网站,今天是 分享到:

中国临床药理学与治疗学 ›› 2018, Vol. 23 ›› Issue (10): 1159-1164.doi: 10.12092/j.issn.1009-2501.2018.10.012

• 药物治疗学 • 上一篇    下一篇

参附注射液对乳腺癌术后化疗患者生存质量及其免疫功能的影响研究

陈 舟,黄 和,陈其余   

  1. 温州医科大学附属第一医院药学部,温州 325000,浙江
  • 收稿日期:2018-06-21 修回日期:2018-07-25 出版日期:2018-10-26 发布日期:2018-10-25
  • 作者简介:陈舟,女,本科 ,中药师,研究方向:中药科学。 Tel: 13868406530 E-mail: chenz220@126.com

Effects of Shenfu injection on the quality of life and immune function on patients with breast cancer after chemotherapy

CHEN Zhou, HUANG He, CHEN Qiyu   

  1. Department of Pharmacy, the First Affiliated Hospital of Wenzhou Medical University, Wenzhou 325000, Zhejiang, China
  • Received:2018-06-21 Revised:2018-07-25 Online:2018-10-26 Published:2018-10-25

摘要:

目的: 研究参附注射液对乳腺癌术后化疗患者生存质量及免疫功能的影响。方法: 选择2016年12月至2017年12月在本院化疗的150例乳腺癌患者为研究对象,按照随机数表法均分为对照组和研究组。对照组给予常规化疗方案,研究组在对照组化疗的基础上联合参附注射液治疗。化疗6个疗程后,比较两组患者临床疗效,分析两组患者化疗前后T细胞亚群、自然杀伤细胞(NK细胞)水平和免疫球蛋白水平,比较两组化疗后的生存质量情况,观察不良反应发生情况。结果: 研究组临床治疗总有效率为96.00%,明显高于对照组的86.67%(P<0.05)。化疗前,两组患者的CD3+、CD4+、CD8+、CD4+/CD8+和NK细胞水平比较差异无统计学意义(P>0.05)。化疗后,两组患者的CD3+、CD4+、CD4+/CD8+和NK细胞水平均升高,研究组高于对照组;CD8+水平均下降,研究组低于对照组,两组比较差异有统计学意义(P<0.05)。化疗后,两组患者的lgG、lgA和lgM水平均下降,且研究组均明显低于对照组(P<0.05)。化疗后,研究组患者功能子量表中的躯体功能得分明显高于对照组,症状子量表中的疲劳、恶心/呕吐和疼痛得分明显低于对照组(P<0.05)。研究组总不良反应率为4.00%,明显低于对照组的14.67%,两组比较差异有统计学意义(P<0.05)。 结论: 参附注射液能有效提高乳腺癌术后化疗患者免疫功能,改善患者术后生存质量,临床疗效显著,临床应用价值高。

关键词: 参附注射液, 乳腺癌, 化疗, 生存质量, 免疫功能

Abstract:

AIM: To study the effect of Shenfu injection on the quality of life and immune function in patients with breast cancer after chemotherapy.  METHODS: A total of 150 patients with breast cancer who received chemotherapy in our hospital from Dec.2016 to Dec.2017 were selected and randomly divided into the study group and the control group according to the random number table method. The control group was given conventional chemotherapy; the study group received extra Shenfu injection treatment on the basis of the control group. After 6 courses of chemotherapy, the clinical efficacy of the two groups was compared. The T cell subgroup, NK cell level, immunoglobulin level and the quality of life of the two groups were analyzed before and after chemotherapy and the occurrence of adverse reactions was observed. RESULTS: The total effective rate of the study group was 96%, which was significantly higher than that of the control group (86.67%) (P<0.05). Before chemotherapy, there was no significant difference in the levels of CD3+, CD4+, CD8+, CD4+/CD8+ and NK cells between the two groups (P>0.05). After chemotherapy, the level of CD3+, CD4+, CD4+/CD8+ and NK cells in the two groups increased, and the increase of the study group was higher than that of the control group. The level of CD8+ decreased and the decrease of the study group was lower than the control group. The two groups were significantly different (P<0.05). After chemotherapy, the lgG, lgA and lgM level of the two groups decreased, and the study group decreased more than the control group (P<0.05). After chemotherapy, the score of somatic function in the functional subscale of the study group was significantly higher than that of the control group. The scores of fatigue, nausea, vomiting and pain in the symptom subscale were significantly lower than those of the control group (P<0.05). The total adverse reaction rate in the study group was 4%, which was significantly lower than that in the control group (14.67%). There was a significant difference between the two groups (P<0.05). CONCLUSION: Shenfu injection can effectively improve the immune function of patients with breast cancer after chemotherapy, and improve the quality of life after operation. The clinical effect is remarkable and worthy of clinical application.

Key words: Shenfu injection, breast cancer, chemotherapy, quality of life, immune function

中图分类号: